## UHS: Universal Health Services, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.5% below STRENGTH zone (3.0-6.0%); PEG 1.87 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($218.04)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Universal Health Services, Inc. (NYSE:UHS) Given Consensus Rating of "Hold" by Brokerages**
- Source: MarketBeat | 20251225T080849 | Neutral | Relevance: 100%
- Universal Health Services, Inc. (NYSE:UHS) has received a consensus "Hold" rating from sixteen brokerages, with an average 12-month price target of $234.14. The company recently reported strong quarterly earnings, beating expectations with an EPS of $5.69 and revenue of $4.50 billion, showing a 13.4% year-over-year increase. Despite some insider share sales, institutional ownership remains high at 86%, and the company declared a quarterly dividend of $0.20.

**2. Burney Co. Sells 9,038 Shares of Universal Health Services, Inc. $UHS**
- Source: MarketBeat | 20251227T080847 | Somewhat-Bullish | Relevance: 100%
- Burney Co. reduced its stake in Universal Health Services, Inc. (NYSE:UHS) by 11.8%, leaving them with 67,814 shares worth approximately $13.86 million. The company reported strong Q3 earnings, surpassing analyst estimates with $5.69 EPS and $4.50 billion in revenue. Despite mixed analyst ratings averaging a "Hold" with a $234.14 target, and some insider selling, institutional investors collectively own 86.05% of the stock.

**3. Ambulatory Care Drives Tenet Healthcare Corporation (THC)'s Strong Earnings Momentum**
- Source: Finviz | 20251225T140500 | Neutral | Relevance: 60%
- Tenet Healthcare Corporation (THC) is experiencing strong earnings momentum, particularly driven by its ambulatory care segment. The company's Q3 2025 results showed a significant increase in adjusted EBITDA, and analysts have maintained positive ratings and price targets due to robust operational execution and growth in outpatient procedures. Tenet also raised its 2025 adjusted EBITDA guidance, reflecting continued profitability and effective cost management.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Guggenheim | $274 | $253 | +8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Guggenheim | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($11.07M) |
| Sells | 3 ($30.51M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (-3.4%)
- First Eagle Investme: 8.4% (+0.0%)
- Blackrock Inc.: 8.0% (-11.9%)
- State Street Corpora: 4.7% (-3.1%)
- FMR, LLC: 3.8% (+0.1%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-1.6% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $31M sold (3 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.87 elevated, pricing in significant growth expectations. Analyst sentiment positive (1 raises, avg +8%). Insider selling cluster ($30.5M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.5B |
| Beta | 1.27 |
| 52W Range | $152.33 - $246.33 |
| Short Interest | 5.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.87 |
| Forward P/E | 9.7 |
| Current P/E | 10.5 |
| YoY Growth | 8.0% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 1.1% to -0.5% (-1.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.5pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.18x) but short-term weakness (below SMA20). RSI neutral at 52. OFD pattern: +MLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.49% (CS: 62) | Neutral |
| RSI_14 | 52.1 | Neutral |
| MACD Histogram | -0.35 | Bearish |
| vs SMA20 | 0.997x | Below |
| vs SMA50 | 1.013x | Above |
| vs SMA200 | 1.182x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $227.64
- **Stop Loss:** $218.04 (4.2% risk)
- **Target:** $237.24 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 137
- **Position Value:** $31,186.68
- **Portfolio %:** 31.19%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-25 (Est: $5.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.95 | $5.69 | +14.9% |
| 2025Q2 | $4.96 | $5.35 | +8.0% |
| 2025Q1 | $4.36 | $4.84 | +11.1% |
| 2024Q4 | $4.18 | $4.92 | +17.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*